Form 8-K - Current report:
SEC Accession No. 0001193125-25-155503
Filing Date
2025-07-03
Accepted
2025-07-03 16:16:10
Documents
12
Period of Report
2025-06-30
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d941822d8k.htm   iXBRL 8-K 23133
  Complete submission text file 0001193125-25-155503.txt   136013

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA urgn-20250630.xsd EX-101.SCH 2840
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE urgn-20250630_lab.xml EX-101.LAB 17993
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE urgn-20250630_pre.xml EX-101.PRE 11254
14 EXTRACTED XBRL INSTANCE DOCUMENT d941822d8k_htm.xml XML 3644
Mailing Address 9 HA'TA'ASIYA ST RA'ANANA L3 4365007
Business Address 9 HA'TA'ASIYA ST RA'ANANA L3 4365007 972 9 770 7601
UroGen Pharma Ltd. (Filer) CIK: 0001668243 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38079 | Film No.: 251105760
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)